In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 3, 2013, Pages 532-539

  King, Martin ^a   Kumar, Praveen ^a   Michel, Deborah ^a   Batta, Ravinderjit ^a   Foldvari, Marianna ^b  

^a Helix BioPharma Corp   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Biphasic vesicles; Dermal pharmacokinetics; HPV infections; Interferon alpha; Lipid based drug delivery; Topical delivery

Indexed keywords

PLACEBO; RECOMBINANT ALPHA2B INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; COATED VESICLE; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; ENCAPSULATION; GUINEA PIG; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; SKIN;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CATTLE; CELL LINE; DRUG DELIVERY SYSTEMS; GUINEA PIGS; INTERFERON-ALPHA; LIPIDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHOLIPIDS; SKIN; TIME FACTORS;

EID: 84879108665     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.01.014     Document Type: Article

References (34)

1. M.R. Prausnitz, S. Mitragotri, and R. Langer Current status and future potential of transdermal drug delivery Nat. Rev. Drug Discov. 3 2004 115 124
2. T. Ghafourian, P. Zandasrar, H. Hamishekar, and A. Nokhodchi The effect of penetration enhancers on drug delivery through skin: a QSAR study J. Controlled Release 99 2004 113 125
3. A.V. Badkar, A.M. Smith, J.A. Eppstein, and A.K. Banga Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats Pharm. Res. 24 2007 1389 1395
4. J. Cazares-Delgadillo, A. Naik, A. Ganem-Rondero, D. Quintanar-Guerrero, and Y.N. Kalia Transdermal delivery of cytochrome C - a 12.4 kDa protein - across intact skin by constant-current iontophoresis Pharm. Res. 24 2007 1360 1368
5. L. Nordquist, N. Roxhed, P. Griss, and G. Stemme Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration Pharm. Res. 24 2007 1381 1388
6. M. Foldvari, I. Badea, P. Kumar, S. Wettig, R. Batta, M.J. King, Z. He, E. Yeboah, K. Gaspar, P. Hull, and N.H. Shear Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections Curr. Drug Deliv. 8 2011 307 319
7. M.J. King, I. Badea, J. Solomon, P. Kumar, K.J. Gaspar, and M. Foldvari Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats Diabetes Technol. Ther. 4 2002 479 488
8. S. Babiuk, M.E. Baca-Estrada, R. Pontarollo, and M. Foldvari Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) J. Pharm. Pharmacol. 54 2002 1609 1614
9. M.J. King, D. Michel, and M. Foldvari Evidence for lymphatic transport of insulin by topically applied biphasic vesicles J. Pharm. Pharmacol. 55 2003 1339 1344
10. M. Foldvari Biphasic vesicles: a novel topical drug delivery system J. Biomed. Nanotechnol. 6 2010 543 557
11. M. Foldvari, I. Badea, S. Wettig, D. Baboolal, P. Kumar, A.L. Creagh, and C.A. Haynes Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum Mol. Pharm. 7 2010 751 762
12. S.A. Gall Human papillomavirus infection and therapy with interferon Am. J. Obstet. Gynecol. 172 1995 1354 1359
13. A.E. Friedman-Kien, L.J. Eron, M. Conant, W. Growdon, H. Badiak, P.W. Bradstreet, D. Fedorczyk, J.R. Trout, and T.F. Plasse Natural interferon alfa for treatment of condylomata acuminata JAMA 259 1988 533 538
14. S.C. Sweetman Martindale: The Complete Drug Reference 2005 Pharmaceutical Press London, UK pp. 640-645
15. P. Thomson Physicians Desk Reference 59 2005 Thompson Healthcare NY, USA
16. M.G. Tovey, and C. Lallemand Safety, tolerability and immunogenicity of interferons Pharmaceuticals 3 2010 1162 1186
17. S.D.R.J. Willis, H.E. Spiegel, D.M. Gibson, and M.D. Nadler Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection Clin. Pharmacol. Ther. 35 1984 5
18. Z.G. Fent K Toxicity of interferon and interleukin Trends Pharm. Sci. 8 1987 5
19. M.J.C.J. Shüller, G. Schernthaner, U. Fogl, M. Wirth, C. Bosse, W. Jäger, and M. Micksche Pharmacokinetic aspects of interferon alfa-after intrahepatic or intraperitoneal administration Semin. Oncol. 19 1992 6
20. E. Radwanski, G. Perentesis, S. Jacobs, E. Oden, M. Affrime, S. Symchowicz, and N. Zampaglione Pharmacokinetics of interferon alpha-2b in healthy volunteers J. Clin. Pharmacol. 27 1987 432 435
21. I. Shah, J. Band, M. Samson, J. Young, R. Robinson, B. Bailey, A.M. Lerner, and A.S. Prasad Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies Am. J. Hematol. 17 1984 363 371
22. P.P.R.M.S Kunzi Cytokine Reference 2000 Academic Press Maryland Heights, MO, USA
23. G.W. Demers, B.J. Sugarman, J.C. Beltran, L.N. Westreich, C.M. Ahmed, J.Y. Lau, Z. Hong, R.E. Lanford, and D.C. Maneval Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles Toxicol. Appl. Pharmacol. 180 2002 36 42
24. K. Cantell, L. Pyhala, and H. Strander Circulating human interferon after intramuscular injection into animals and man J. Gen. Virol. 25 1974 453 455
25. N. Weiner, N. Williams, G. Birch, C. Ramachandran, C. Shipman Jr., and G. Flynn Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model Antimicrob. Agents Chemother. 33 1989 1217 1221
26. A. Ghahary, E.E. Tredget, Q. Shen, R.T. Kilani, P.G. Scott, and M. Takeuchi Liposome associated interferon-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig Mol. Cell. Biochem. 208 2000 129 137
27. R.B.P. Kumar, G. LaBine, J. Shen, K. Gaspar, J. Docherty, and M. Foldvari Stabilization of interferon alpha-2b in a topical cream Pharm. Tech. 33 2009 6
28. E.V. Buehler Delayed contact hypersensitivity in the guinea pig Arch. Dermatol. 91 1965 171 177
29. J.A. Armstrong Cytopathic effect inhibition assay for interferon: microculture plate assay Methods Enzymol. 78 1981 381 387
30. G.K. McEvoy AHFS Drug Information 2001 American Society of Hospital-System Pharmacists Inc. Bethesda, MD, USA
31. K. Egbaria, C. Ramachandran, D. Kittayanond, and N. Weiner Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies Antimicrob. Agents Chemother. 34 1990 107 110
32. D.A. Eppstein, and W.E. Stewart 2nd Altered pharmacological properties of liposome-associated human interferon-alpha J. Virol. 41 1982 575 582
33. L. Yang, W. Yang, D. Bi, and Q. Zeng A novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained release Eur. J. Pharm. Biopharm. 64 2006 9 15
34. X.-H.W.J. Qui, F. Geng, R. Liu, J.-W. Zhang, and Y.-H. Xu Multivesicular liposomal formulations for the sustained delivery of interferon α Acta Pharm. Sin. 26 2005 6